| Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development JW Lee, M Kelley, LE King, J Yang, H Salimi-Moosavi, MT Tang, JF Lu, ... The AAPS journal 13, 99-110, 2011 | 253 | 2011 |
| Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1) M Sung, X Tan, B Lu, J Golas, C Hosselet, F Wang, L Tylaska, L King, ... Molecular cancer therapeutics 17 (1), 243-253, 2018 | 146 | 2018 |
| A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions M Damelin, A Bankovich, J Bernstein, J Lucas, L Chen, S Williams, A Park, ... Science translational medicine 9 (372), eaag2611, 2017 | 130 | 2017 |
| Agricultural fires in the southeastern U.S. during SEAC4RS: Emissions of trace gases and particles and evolution of ozone, reactive nitrogen, and organic aerosol X Liu, Y Zhang, LG Huey, RJ Yokelson, Y Wang, JL Jimenez, ... Journal of Geophysical Research: Atmospheres 121 (12), 7383-7414, 2016 | 117 | 2016 |
| The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis S Cahue, L Sharma, D Dunlop, M Ionescu, J Song, T Lobanok, L King, ... Osteoarthritis and cartilage 15 (7), 819-823, 2007 | 116 | 2007 |
| Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. WP Maksymowych, AR Poole, L Hiebert, A Webb, M Ionescu, T Lobanok, ... The Journal of Rheumatology 32 (10), 1911-1917, 2005 | 98 | 2005 |
| Therapeutic monoclonal antibody concentration monitoring: free or total? B Kuang, L King, HF Wang Bioanalysis 2 (6), 1125-1140, 2010 | 97 | 2010 |
| Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years … SMM Verstappen, AR Poole, M Ionescu, LE King, M Abrahamowicz, ... Arthritis research & therapy 8, 1-9, 2006 | 77 | 2006 |
| Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy RH Mullan, C Matthews, B Bresnihan, O FitzGerald, L King, AR Poole, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 73 | 2007 |
| Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation M Kelley, AB Ahene, B Gorovits, J Kamerud, LE King, T McIntosh, J Yang The AAPS journal 15, 646-658, 2013 | 72 | 2013 |
| A new turbulence closure model for boundary layer flows with strong adverse pressure gradients and separation D Johnson, L King 22nd Aerospace Sciences Meeting, 175, 1984 | 66 | 1984 |
| Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team LE King, E Farley, M Imazato, J Keefe, M Khan, M Ma, KS Pihl, P Sriraman The AAPS journal 16, 504-515, 2014 | 64 | 2014 |
| Detection of aggrecanase-and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration MJ Janusz, CB Little, LE King, EB Hookfin, KK Brown, SA Heitmeyer, ... Osteoarthritis and cartilage 12 (9), 720-728, 2004 | 64 | 2004 |
| Workshop report: Crystal City VI—bioanalytical method validation for biomarkers ME Arnold, B Booth, L King, C Ray The AAPS journal 18, 1366-1372, 2016 | 62 | 2016 |
| A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART® A Betts, N Haddish-Berhane, DK Shah, PH van der Graaf, F Barletta, ... The AAPS journal 21, 1-16, 2019 | 57 | 2019 |
| Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response TH Kim, M Stone, U Payne, X Zhang, M Ionescu, T Lobanok, L King, ... Arthritis & Rheumatism 52 (3), 885-891, 2005 | 57 | 2005 |
| A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate DK Shah, LE King, X Han, JA Wentland, Y Zhang, J Lucas, ... The AAPS journal 16, 452-463, 2014 | 55 | 2014 |
| Preclinical to clinical translation of antibody-drug conjugates using PK/PD modeling: a retrospective analysis of inotuzumab ozogamicin AM Betts, N Haddish-Berhane, J Tolsma, P Jasper, LE King, Y Sun, ... The AAPS journal 18, 1101-1116, 2016 | 53 | 2016 |
| 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2–hybrid LBA/LCMS, ELN & regulatory agencies’ input) D Dufield, H Neubert, F Garofolo, L Kirkovsky, L Stevenson, I Dumont, ... Bioanalysis 6 (23), 3237-3249, 2014 | 48 | 2014 |
| Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1) AP Singh, KF Maass, AM Betts, KD Wittrup, C Kulkarni, LE King, A Khot, ... The AAPS journal 18, 861-875, 2016 | 46 | 2016 |
Dr. Dhaval K. ShahAssociate Professor, Department of Pharmaceutical Sciences, SUNY BuffaloVerified email at buffalo.edu
